Can GW Pharmaceuticals Stock Bounce Back?

Shares of GW Pharmaceuticals (NASDAQ: GWPH) have been sliding since the company reported quarterly results that were arguably positive. GW Pharmaceuticals is enjoying a relatively successful launch of Epidiolex, a cannabidiol (CBD) tincture approved in 2018 to treat patients with severe childhood-onset epilepsy. Pivotal studies leading to the drug's approval showed impressive reductions in the frequency of convulsive seizures experienced by patients with Dravet syndrome and Lennox-Gastaut syndrome.